Nanotechnology Advances in Drug Delivery - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nanotechnology Advances in Drug Delivery
Nanotechnology is emerging as a tool for resolving challenge in delivering poorly water soluble and highly potent drugs.


Pharmaceutical Technology


Established drug delivery companies, start-ups, and academia are advancing nanotechnology in oral, injectable, transdermal, and implantable systems as a means to improve bioavailability for a variety of drugs.

Nanotechnology at work


Table I: Select companies involved in nanotechnology-based drug delivery.
Start-up companies as well as established companies are pursuing commercial development of nanotechnology-based delivery systems (see Table I). Elan Corporation's "NanoCrystal" technology, for example, is designed to improve the delivery of poorly water-soluble drugs by transforming them into nanometer-sized particles, typically less than 1000 nm in diameter, which are produced by milling the drug substance using a proprietary wet-milling technique, according to company information. The NanoCrystal particles of the drug are stabilized against agglomeration by surface adsorption of select stabilizers. The result is an aqueous dispersion of the drug substance that behaves like a solution, a "NanoCrystal Colloidal Dispersion," which can be processed into finished-dosage forms.

Elan has four products, approved in the United States, which use the NanoCrystal technology: Wyeth's (Madison, NJ) "Rapamune" (sirolimus), Merck & Co.'s (Whitehouse Station, NJ), "Emend" (aprepitant), Abbott Laboratories' (Abbott Park, IL) "Tricor" (fenofibrate), and Par Pharmaceutical's (Woodcliff Lake, NJ) "Megace ES" (megestrol). Elan also has a pact with Abbott and AstraZeneca to use the NanoCrystal technology in developing a combination product of fenofibrate and AstraZeneca's (London) "Crestor" (rosuvastatin). Elan is partnered with Johnson & Johnson (J&J, New Brunswick, NJ) for the NanoCrystal technology in J&J's long-acting injectable form of paliperidone that is under development.

Baxter Healthcare's "Nanoedge" dispersion technology is another example of a commercial nano-based approach. The particle size is reduced to a nanometer size range to increase the surface area, thereby increasing the rate of dissolution by using two complementary processes, homogenization and precipitation.

pSivida (Perth, Australia), which recently signed a $165-million pact with Pfizer for ophthalmic delivery, owns the right to develop and commercialize "BioSilicon," a nanostructured porous silicon for drug delivery. BioSilicon is composed of elemental silicon that is processed to create a honeycomb structure of pores. These pores can be formed into various shapes and sizes and filled with drugs, including small chemical entities, peptides, and proteins, according to the company. pSivida is targeting the technology for formulating poorly water-soluble drugs and for controlled, slow-release drug delivery.

pSivida's lead product using BioSilicon is "BrachySil," a brachytherapy treatment in Phase II trials, which involves the localized delivery of radioactive agents directly into a tumor. The product is licensed to Beijing Med-Pharm Corp. (Plymouth Meeting, PA).

Insert Therapeutics (Pasadena, CA), a subsidiary of the nanotechnology company Arrowhead Research Corporation (Pasadena, CA), is using a nano-engineered polymeric drug delivery system,"Cyclosert," to deliver small molecules and nucleic acids. The system is based on linear cyclodextrin-containing polymers. Insert Therapeutics is licensing the technology to R&D Biopharmaceuticals GmbH (Planegg, Germany) to deliver the anticancer agent tubulysin A. R&D Biopharmaceuticals recently signed a pact with Insert Therapeutics to use the technology in developing epothilones, microtubule depolymerization inhibitors used as anticancer therapies.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here